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Abstract 
Identification and characterization of large protein complexes is a mainstay of 
biochemical toolboxes. Utilization of cross-linking chemicals can facilitate the 
capture and identification of transient or weak interactions of a transient nature (1, 2). 
Here we describe a detailed methodology for cell culture based proteomic approach. 
We describe the generation of cells stably expressing green fluorescent protein (GFP)-
tagged proteins under the tetracycline-inducible promoter and subsequent proteomic 
analysis of GFP-interacting proteins. We include a list of proteins that were identified 
as interactors of GFP. 
 
1. Introduction 
Ectopic introduction of an inducible GFP-tagged protein in cells is a useful technique 
for characterization of protein-protein interactions. Introduction of a pcDNA-
5/FRT/TOTM expression vector (Invitrogen) GFP-tagged gene with a pOG44 Flip-
recombinase expression plasmid into Flp-INTM T-RExTM 293 cells (Invitrogen) will 
integrate the tagged gene into a single pre-designated FRT site. Following integration 
of the GFP-tagged gene, cells are treated with hygromycin to select for cells that have 
successfully integrated the pCDNA 5/FRT/TO vector containing the gene of interest. 
Cells are then maintained in growth medium supplemented with hygromycin. The 
stable integration of GFP-tagged genes in T-RexTM 293 cells allows for real-time 
detection of protein expression and troubleshooting for appropriate induction time and 
dose of doxycycline or tetracycline. Once stable cells are established, a time-course of 
doxycyline or tetracycline can be performed to determine appropriate duration to 
achieve desired levels of protein expression (Figure 1).  
 
Purification of GFP or GFP-tagged proteins in complex is performed in concert with 
the addition of dithiobis succinimidyl propionate (DSP) during lysis. DSP has dual 
NHS esters (see DSP structure in Figure 2), thus targeting primary amines in protein 
complexes and forming a conjugated network of proteins (3, 4).  Lysis buffer is gently 
supplemented with DSP prior to lysis in a dropwise fashion to minimize precipitation, 
appropriate amount of lysis buffer is then added to cells and allows DSP to interact 
with primary amines in proteins and complexes of the proteins. Figure 3 illustrates a 
graphical representation of the pull-down workflow and protein identification by mass 
spectrometry. 
 
2. Materials 
1. TREx 293 cell lines are available from Invitrogen (R780-07). Maintain cells in 
DMEM supplemented with 10% fetal bovine serum (FBS, Hyclone), 2 mM L-
glutamine (Gibco), 100 U/ml pencillin, 200 µg/ml streptomycin, 15 µg/ml 
blasticidin and 100 µg/ml zeocin. 
2. Recombinase Flp-IN pOG44 (V6005-20) and pCDNA5 FRT/TO (V6520-20) 
can be purchased from Invitrogen. 
3. Clone individual genes of interest into pCDNA5 FRT/TO using convenient 
multiple cloning sites. 
4. Lysis buffer is prepared as 40 mM HEPES pH 7.4, 120 mM NaCl, 1 mM 
EDTA, 10 mM sodium pyrophosphate, 50 mM NaF, 1.5 mM sodium 
orthovanadate, 1% Triton, 1 tablet complete protease inhibitor cocktail per 25 
ml (5).  
5. Prepare dithiobis succinimidyl propionate (DSP, Pierce) 200 mg/ml in 
dimethyl sulfoxide (prepare fresh). DSP forms an NHS ester with primary 
amines and is cleaved upon reduction with dithiothreitol (DTT). This property 
allows for purification of conjugated DSP-protein complexes and release upon 
addition of the reducing agent in the final steps just prior to performing SDS-
PAGE.  
6. Equilibrate GFP-trap beads (ChromoTek) in lysis buffer (above). Finally, 
prepare 50% slurry. 
7. 1.5 mm NuPAGE Bis-Tris 10% precast gels (Invitrogen). 
8. MOPS SDS-PAGE running buffer (50 mM MOPS, 50 mM Tris Base, 0.1% 
SDS, 1 mM EDTA, pH 7.7). 
9. Spin X columns Corning® Costar® Spin-X® centrifuge tube filters cellulose 
acetate membrane, pore size 0.45 m, sterile. 
10. SimplyBlue™ SafeStain (Invitrogen)  
11. Triethylammonium bicarbonate (Sigma) 
12. Sequencing grade modified trypsin (Promega) 
 
3.1 Transfection and establishing a GFP stable cell line 
1. Plate ~1 x 106 (~60% confluent) in a 10-cm dish in complete medium lacking 
zeocin/blasticidin. Place cells in a 37oC, 5% CO2 incubator overnight.  
2. Pre-warm 1 ml of Opti-MEM serum free medium (Life Technologies) in a 15-
ml conical tube. 
3. Add 9 µg pOG44 plasmid and 1 µg of pCDNA5/FRT/TO-GFP vector (Note: 
maintain a 9:1 ratio of pOG44 with pCDNA5/FRT/TO-GFP when scaling 
target cell dish size).  
4. Add 25 µl of polyethylenemine (1 mg/ml) (Polysciences) or other transfection 
reagent to transfection medium and mix by tapping or vortexing for 15 s 
5. Leave the transfection mix for 15 min at room temperature. 
6. Add the entire transfection mixture to the target cell dish in a drop-wise 
fashion and return cells to the incubator. 
7. 24 h post-transfection split cells into 3 dishes and maintain in DMEM, 10% 
FBS, L-glutamine, penicillin and streptomycin for 24 h. 
8. Exchange medium with fresh medium containing 15 µg/ml blasticidin and 100 
µg/ml hygromycin. Hygromycin selection will cause the death of 
untransfected cells lacking the integration of pCDNA5/FRT/TO/GFP vector 
into the FRT site. Replace medium every three days. As a negative control, 
use the selection medium in untransfected control cells. 
9. Check cells daily until majority of cells are dead and a number of colonies 
have formed. Then begin the expansion of cells for protein expression 
analysis. 
10. Test doxycycline (20 ng/ml) or tetracycline (1 µg/ml) induction time course 
(Figure 1) for GFP-expression. Fluorescence microscopy can also be used to 
ensure that every cell expresses GFP upon induction with doxycycline or 
tetracycline.  
3.2 Purification of GFP-interacting proteins from stable cell lines using DSP 
crosslinking agent 
1. Induce GFP protein expression with 20 ng/ml doxycycline for a defined time. 
2. Wash cells once in ice-cold PBS. Gently add PBS to prevent dislodging cells 
during washing steps. 
3. Lyse by scraping the desired number and size (10cm-15cm) of semi-confluent 
dishes in complete lysis buffer (above) with 2.5 mg/ml DSP. Transfer lysates 
onto a falcon tube. 
4. Keep the lysates on ice for 30 minutes, then quench crosslinking reaction by 
adding 6.25 ml of 1M Tris-HCl, pH 7.4 per 25ml lysis buffer (200 mM Tris-
HCl final) and incubate for further 30 minutes. (Lysates can be snap frozen in 
liquid nitrogen and stored at -80 oC this stage) 
5. Spin lysates at 10,000 x g for 30 min at 4 oC. Collect a small aliquot of cleared 
lysate for immunoblot analysis.  
6. Filter the lysates through a filter column to clear the lysate of any debris. 
7. To clarified lysate, add 50 µl packed sepharose or agarose beads for 1h at 4 
oC. This pre-clearing step minimizes non-specific interactions to solid-phase.  
8. To the cleared lysate (10-60 mg total protein), add 50 µl of equilibrated GFP-
rap beads and incubate for 4 h on a roller at 4oC.  
9. Wash beads in 4 x 10 ml of complete lysis buffer containing 0.5M NaCl. 
Addition of NaCl removes weak or low affinity spurious interactions.  
10. Wash beads with 10 ml of 50 mM Tris-HCl, pH 7.5, 0.1mM EGTA. 
11. Reconstitute beads in 60 µl of 1X LDS sample buffer with 0.1M DTT final, 
incubate for 1 h at 37 oC, boil for 5 min at 95 oC. DTT reduces disulfide bond 
from DSP to remove cross-linking of proteins.  
12. Isolate denatured proteins from GFP-trap beads by spinning through spin X 
columns. 
3.3 Gel electrophoresis of GFP purified protein complexes 
1. Prepare a 10% NuPAGE Bis-Tris (1.5 mm thick) gel for electrophoretic 
separation of proteins. Rinse wells thoroughly with MOPS running buffer.  
2. Load equal amounts of control GFP and GFP-protein of interest into 
alternating wells (leave empty wells between samples to minimize potential 
cross contamination during loading).  
3. Resolve proteins at ~160 volts for ~45 minutes.  
4. Stain using mass spectrometry grade staining reagent containing Coomassie 
blue dye or Simply Blue. 
5. Image gel in clean petri dish, avoid unnecessary handling to minimize keratin 
contamination.  
 
4.1 In gel Trypsin digestion 
1. Excise bands of interest for each sample lane (See example Figure 4A). 
2. Cut bands into small 1-2 mm cubes with a clean scalpel. Place into clean 1.5 
ml centrifuge tubes, minimize keratin contamination by changing gloves 
frequently. 
3. Wash gel bands sequentially in 500 µl of 1) water, 2) 50% acetonitrile, 3) 50 
mM NH4HCO3 (ammomium bicarbonate; prepared fresh) and 4) 50% 
acetonitrile/50 mM NH4HCO3. Place samples on shaker for 10 min at room 
temperature for each wash step. Aspirate wash solution after each step. 
4. In-gel alkylation and reduction steps:  
a. To each tube add 75 µl of freshly prepared 10 mM DTT/50 mM  
NH4HCO3 and incubate for 20 minutes at 37oC.  Remove solution and 
proceed to alkylation step. 
b. Add 75 µl of freshly prepared 100 mM iodoacetamide/50 mM  
NH4HCO3 and incubate in dark at room temperature for 20 min.  
6. Remove liquid and wash bands in 50 mM NH4HCO3 for 10 min at room 
temperature.  
7. Remove liquid and replace with 50% acetonitrile/50 mM NH4HCO3 to remove 
any dye stain. Repeat wash steps until gel pieces are colorless.  
8. Add 300 µl of acetonitrile to each tube for 10-15 minutes. Speed vacuum 
away additional acetonitrile, dry gels pieces will appear opaque. 
9. Re-swell gel pieces in 25 mM triethylammonium bicarbonate containing 5 
µg/ml of sequencing grade modified porcine trypsin. Place on shaker at 30 oC. 
After 20-30 minutes, check gel pieces are adequately soaked in solution. If 
not, add more triethylammonium bicarbonate to assure coverage of bands. 
Digest gel bands overnight. 
10. Following overnight digest, add an equivalent volume of acetonitrile to each 
gel piece and shake for 10-15 minutes.  
11. Transfer supernatant onto a clean tube. Place directly into vacuum centrifuge 
and spin until dry.  
12. To gel pieces, add additional 100 µl of 50% acetonitrile/2.5% formic acid and 
shake. Add supernatant to dried tubes from step 11. Transfer tubes to vacuum 
centrifuge until dry. Samples are now ready for 1-dimensional HPLC 
electrospray ionization. Samples can be stored at -80 oC until ready to perform 
mass spectrometry analysis.  
4.2 Mass spectrometry 
1. Solubilize digested peptide samples into a working volume of HPLC grade 5% 
acetonitrile/0.1% formic acid for injection into the HPLC autosampler, 
typically 20-30 µl volumes are reasonable.  
2. Resulting peptides are injected onto a 3-µm C18 reversed-phase (RP) resin 
column (Acclaim PepMap100, 75 µm × 15 cm). Peptides are eluted into a 
Thermo LTQ Orbitrap over a 40-minute gradient of 2% acetonitrile/0.1% 
formic acid to 50% of a 90% acetonitrile/0.08% formic acid solvent.   
3. Spectra are collected under data-dependent analysis selecting for the 5 most 
intense MS ions to be fragmented for MS-MS sequencing (See Figure 4B for 
example). Depending on instrumentation, additional ion fragmentation can be 
integrated into the data-dependent analysis. Exclusion lists for repeat ions can 
be developed to increase spectral analysis.  
4. Raw data files/spectra can be submitted to in-house proprietary (Mascot, 
Sequest Sorcerer) or non-proprietary (Global proteome machine analysis 
www.gpm.org) database search softwares. Once spectra have been assigned 
and proteins identified, the lists of interacting proteins can be interrogated 
using ontological and cluster analysis softwares (see section 4.3). Quantitative 
analysis can be performed using Scaffold, a statistical package for 
determination of data quality and spectral assignments (6). 
 
4.3 Bioinformatics analysis of dataset 
Analysis of shotgun proteomics lists can be conducted using proprietary 
software such as Ingenuity Pathways Analysis or public databases such as the 
Database for Annotation, Visualization and Integrated Discovery (DAVID, 
http://david.abcc.ncifcrf.gov) (7, 8). These software packages allow for 
delving into the dataset and assigning molecular function and disease 
correlation along with developing various other ontological connections within 
the dataset. Gene Ontology (geneontology.org) can also be used to interrogate 
and determine term enrichment within a dataset (9). Cell localization, function 
and disease associations can be assigned to groups of proteins to better 
understand characteristics of the proteome cohort (10). Solid phase interactors 
(i.e. GFP binders) can be compared to the CRAPome database of non-specific 
interactors as well (crapome.org) (5). This repository is useful towards 
determining ruling out non-specific interactions.   
 
Notes and Conclusions:  
Affinity purification of target protein complexes provides a convenient way to 
identify novel binding partners involved in biological processes. Inclusion of 
GFP tags allows for determination of transfection efficiency by visualization. 
One caveat is the effect of the large tag on native interactions. Considering this 
caveat, a strategy to tag target proteins either at the N or C terminus or 
alternatively at an internal site could provide insight into the effects of GFP 
fusion on native protein interactions. Careful determination of the induction 
time for the GFP fusion protein should be considered for potential spurious 
interactions due to heightened overexpression and effects of high abundance 
peptides masking identification of lower abundance but biologically important 
interactions. Using another method of fractionation can improve proteome 
identification and minimize dampening of signal for low abundance peptides 
(i.e. strong cation or strong anion HPLC fractionation of peptides or size 
exclusion chromatography of proteins prior to tryptic digestion). The 
identification of protein complexes can yield a great deal of information in 
terms of protein function and involvement in biological processes. The above 
protocol provides a detailed approach towards conducting protein network 
characterization using mass spectrometry based technologies. The inclusion of 
a list of human proteins that interact with GFP under the experimental 
conditions described above will allow researchers to exclude these as 
contaminants in similar proteomic approach looking at potential interactors of 
GFP-tagged proteins (Table 1). 
 
We have employed the above methodology routinely for many proteomic 
studies (11-14) and continue to do so. Affinity purification of protein 
complexes and analysis by mass-spectrometry is a widely used technique and 
so variations to the above methodology also exist. 
 
 
Acknowledgements: 
 
We thank Kirsten McLeod and Janis Stark for help with tissue culture, 
Thomas Macartney for cloning pCDNA5/FRT/TO/GFP, and the staff at the 
Sequencing Service (School of Life Sciences, University of Dundee, Scotland) 
for DNA sequencing. We thank Dave Campbell and the mass-spectrometric 
team at the MRC Protein Phosphorylation and Ubiquitylation Unit for 
optimization of protocols relating to sample processing for mass-spectrometry. 
TDC is supported by the UK MRC Career Development Fellowship. GS is 
supported by the UK Medical Research Council and the pharmaceutical 
companies supporting the DSTT (AstraZeneca, Boehringer-Ingelheim, 
GlaxoSmithKline, Merck-Serono, Pfizer and Johnson & Johnson). 
 
 
References: 
(1) Huang, B.X., and Kim, H.Y. (2013) Effective identification of Akt interacting 
proteins by two-step chemical crosslinking, co-immunoprecipitation and mass 
spectrometry. PloS one. 8, e61430 
(2) Gao, M., McCluskey, P., Loganathan, S.N., and Arkov, A.L. (2014) An in 
vivo crosslinking approach to isolate protein complexes from Drosophila 
embryos. Journal of visualized experiments : JoVE.  
(3) Kim, K.M., Yi, E.C., and Kim, Y. (2012) Mapping protein receptor-ligand 
interactions via in vivo chemical crosslinking, affinity purification, and 
differential mass spectrometry. Methods. 56, 161-165 
(4) Corgiat, B.A., Nordman, J.C., and Kabbani, N. (2014) Chemical crosslinkers 
enhance detection of receptor interactomes. Frontiers in pharmacology. 4, 171 
(5) Mellacheruvu, D., Wright, Z., Couzens, A.L., Lambert, J.P., St-Denis, N.A., 
Li, T., Miteva, Y.V., Hauri, S., Sardiu, M.E., Low, T.Y., Halim, V.A., 
Bagshaw, R.D., Hubner, N.C., Al-Hakim, A., Bouchard, A., Faubert, D., 
Fermin, D., Dunham, W.H., Goudreault, M., Lin, Z.Y., Badillo, B.G., Pawson, 
T., Durocher, D., Coulombe, B., Aebersold, R., Superti-Furga, G., Colinge, J., 
Heck, A.J., Choi, H., Gstaiger, M., Mohammed, S., Cristea, I.M., Bennett, 
K.L., Washburn, M.P., Raught, B., Ewing, R.M., Gingras, A.C., and 
Nesvizhskii, A.I. (2013) The CRAPome: a contaminant repository for affinity 
purification-mass spectrometry data. Nature methods. 10, 730-736 
(6) Searle, B.C. (2010) Scaffold: a bioinformatic tool for validating MS/MS-based 
proteomic studies. Proteomics. 10, 1265-1269 
(7) Yang, L.J., Ma, D.Q., and Cui, H. (2014) Proteomic analysis of immature rat 
pups brain in response to hypoxia and ischemia challenge. International 
journal of clinical and experimental pathology. 7, 4645-4660 
(8) Huang da, W., Sherman, B.T., and Lempicki, R.A. (2009) Systematic and 
integrative analysis of large gene lists using DAVID bioinformatics resources. 
Nature protocols. 4, 44-57 
(9) Carnielli, C.M., Winck, F.V., and Paes Leme, A.F. (2015) Functional 
annotation and biological interpretation of proteomics data. Biochimica et 
biophysica acta. 1854, 46-54 
(10) Pawar, H., Kashyap, M.K., Sahasrabuddhe, N.A., Renuse, S., Harsha, H.C., 
Kumar, P., Sharma, J., Kandasamy, K., Marimuthu, A., Nair, B., Rajagopalan, 
S., Maharudraiah, J., Premalatha, C.S., Kumar, K.V., Vijayakumar, M., 
Chaerkady, R., Prasad, T.S., Kumar, R.V., Kumar, R.V., and Pandey, A. 
(2011) Quantitative tissue proteomics of esophageal squamous cell carcinoma 
for novel biomarker discovery. Cancer biology & therapy. 12, 510-522 
(11) Vogt, J., Dingwell, K.S., Herhaus, L., Gourlay, R., Macartney, T., Campbell, 
D., Smith, J.C., and Sapkota, G.P. (2014) Protein associated with SMAD1 
(PAWS1/FAM83G) is a substrate for type I bone morphogenetic protein 
receptors and modulates bone morphogenetic protein signalling. Open 
biology. 4, 130210 
(12) Al-Salihi, M.A., Herhaus, L., Macartney, T., and Sapkota, G.P. (2012) USP11 
augments TGFbeta signalling by deubiquitylating ALK5. Open biology. 2, 
120063 
(13) Herhaus, L., Al-Salihi, M., Macartney, T., Weidlich, S., and Sapkota, G.P. 
(2013) OTUB1 enhances TGFbeta signalling by inhibiting the ubiquitylation 
and degradation of active SMAD2/3. Nature communications. 4, 2519 
(14) Herhaus, L., Al-Salihi, M.A., Dingwell, K.S., Cummins, T.D., Wasmus, L., 
Vogt, J., Ewan, R., Bruce, D., Macartney, T., Weidlich, S., Smith, J.C., and 
Sapkota, G.P. (2014) USP15 targets ALK3/BMPR1A for deubiquitylation to 
enhance bone morphogenetic protein signalling. Open biology. 4, 140065 
 
 
Figure Legends 
Figure 1. A time course of doxycycline induction of GFP-expression in T-Rex 
293 GFP cells. Establishing a time course of robust induction of the target 
protein to determine appropriate amount of protein production for interaction 
analysis. Here 6-16 hours of doxycycline induction is appropriate to perform 
protein isolation and downstream mass spectrometry analysis.  
 
Figure 2. Dithiobis (succinimidyl propionate): In blue brackets indicates 
carbodiimide that reacts with primary amines releasing the NHS ring while 
cross-linking polypeptides, red disulfide bond indicates bond that reacts with 
reducing reagent to cleave linkage and release cross-linked proteins or 
polypeptides.  
 
Figure 3. Schematic work-flow for GFP-trap purification and mass 
spectrometry analysis of co-purified proteins.  
 
Figure 4. A. Affinity-purified GFP was resolved by SDS-PAGE 
electrophoeresis with molecular weight markers (kDa) indicated in the first 
lane. Brackets indicate one excised gel-piece, which was tryptically digested 
for mass spectrometric electrospray analysis. B. Identification of a prominent 
protein from the 100 kDa excised band in GFP lane.  GFP interactors are 
compared to target protein of interest to exclude non-specific GFP or bead 
interacting proteins Included in Table 1 are highly enriched promiscuous GFP 
contaminants that can be excluded from target protein pulldown analysis.  
 
Table 1. GFP-binding proteins in a DSP cross-linked pulldown experiment. 
Proteins are rank ordered by normalized spectral count enrichment using 
Scaffold software (v.4.2.1). 
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 Gene Symbol 
Spectral 
Count 
(Normalized ) 
MW 
(kDa) Gene Symbol 
Spectral 
Count 
(Normalized ) 
MW 
(kDa) Gene Symbol 
Spectral 
Count 
(Normalized ) 
MW 
(kDa) 
ACTN4 233.77 105 HNRNPA2B1 58.443 37 SFPQ 29.221 76 
EPPK1 204.55 556 MARS 58.443 101 AHCY 29.221 48 
PLEC 204.55 532 NUP93 58.443 93 SMC4 29.221 147 
GTF2I 175.33 112 NUMA1 58.443 238 KRT18 29.221 48 
PRDX1 146.11 22 PHGDH 58.443 57 DDX5 29.221 69 
YWHAZ 146.11 28 GDI1 58.443 51 MYO6 29.221 150 
DSG1 146.11 114 YWHAG 58.443 28 UBA1 29.221 118 
EEF1A1 116.89 50 PSMA7 58.443 28 YWHAQ 29.221 28 
YWHAE 116.89 29 TPM3 58.443 33 SDHA 29.221 ? 
GRP78 116.89 72 USP5 58.443 96 RPS4X 29.221 30 
RPS27A 116.89 18 NUP107 58.443 106 DNAJC7 29.221 56 
UBA52 116.89 15 RAE1 58.443 41 CSDE1 29.221 89 
ENO1 116.89 47 PRPF6 58.443 107 UBAP2L 29.221 115 
GNB2L1 116.89 35 TAGLN2 58.443 22 LDHB 29.221 37 
ALB 116.89 69 RPL11 58.443 20 NUP88 29.221 84 
KRT77 116.89 62 SDHB 58.443 ? RPSA 29.221 33 
EEF1A2 87.664 50 AARS 58.443 107 CDC5L 29.221 92 
ACTN1 87.664 103 HIST1H4A 58.443 11 PCNA 29.221 29 
TUFM 87.664 50 RAB5C 58.443 23 UPF1 29.221 124 
RPS3 87.664 27 MIF 58.443 12 GDI2 29.221 51 
NONO 87.664 54 MOV10 58.443 114 COPB2 29.221 102 
SF3B3 87.664 136 UHRF1 58.443 90 PHB2 29.221 33 
PCMT1 87.664 25 FUBP1 58.443 68 HDLBP 29.221 141 
ACLY 87.664 121 ACTC1 29.221 42 PDIA3 29.221 57 
VCL 87.664 124 ACTA1 29.221 42 ADAR 29.221 136 
PDIA6 87.664 48 ACTBL2 29.221 42 RTCB 29.221 55 
GRP94 87.664 92 POTEE 29.221 121 ADE2/PAICS 29.221 47 
MCM6 87.664 93 USP9X 29.221 292 ALDH18A1 29.221 87 
NUP98 87.664 198 CSNK1D 29.221 47 PSMB5 29.221 28 
PRDX4 87.664 31 CNOT1 29.221 267 SHMT2 29.221 56 
PCCB 87.664 58 CCT2 29.221 57 DDX1 29.221 82 
TPI1 87.664 31 ATP5A1 29.221 60 FKBP4 29.221 52 
HNRNPUL1 87.664 96 CCT8 29.221 60 RPS3A 29.221 30 
PDAP1 87.664 21 EIF4A1 29.221 46 MST4 29.221 47 
CLTC 58.443 192 EIF4A2 29.221 46 FAM115A 29.221 102 
ACTG1 58.443 42 MCM3 29.221 91 OGT1 29.221 117 
SPTAN1 58.443 285 MCM7 29.221 81 HNRNPH1 29.221 49 
EPRS 58.443 171 DDB1 29.221 127 TPM4 29.221 29 
SPTBN1 58.443 275 PABPC4 29.221 71 NPEPPS 29.221 103 
NUP214 58.443 214 PABPC1 29.221 71 KIF11 29.221 119 
RANBP2 58.443 358 NUP205 29.221 228 RPL4 29.221 48 
HNRNPM 58.443 78 SMC3 29.221 142 PUM1 29.221 126 
GART 58.443 108 PARP1 29.221 113 TARS 29.221 83 
HSPD1 58.443 61 NUP188 29.221 196 ALDOA 29.221 39 
NUP155 58.443 155 PSMD1 29.221 106 RAN 29.221 24 
PRDX2 58.443 22 RAD50 29.221 154 RPS11 29.221 18 
MTHFD1 58.443 102 GAPDH 29.221 36 DIAPH1 29.221 141 
HNRNPU 58.443 91 PSMC5 29.221 46 HNRNPA3 29.221 40 
CCT4 58.443 58 MCM4 29.221 97 NAP1L1 29.221 45 
TCP1 58.443 60 VCP 29.221 89 BUB3 29.221 37 
HNRNPA1 58.443 39 LARS 29.221 134 PDCD6IP 29.221 96 
YWHAH 58.443 28 IKBKAP 29.221 150 RPL10A 29.221 25 
KHSRP 58.443 73 DARS 29.221 57 RPS8 29.221 24 
SND1 58.443 102 SFPQ 29.221 76 LDHA 29.221 37 
Table&1.&&
 Gene Symbol 
Spectral 
Count 
(Normalized ) 
MW 
(kDa) Gene Symbol 
Spectral 
Count 
(Normalized ) 
MW 
(kDa) 
ABCE1 29.221 67 CKAP4 29.221 66 
ILF3 29.221 95 RBM39 29.221 59 
DNAJC10 29.221 91 EIF6 29.221 27 
KRT31 29.221 47 PMPCB 29.221 54 
KRT35 29.221 50 RPL13A 29.221 24 
KRT33B 29.221 46 CSTF1 29.221 48 
KRT33A 29.221 46 PPA1 29.221 33 
C14orf166 29.221 28 MICAL1   29.221 118 
HSD17B10 29.221 27 TFAM 29.221 29 
RPL17 29.221 21 SEC22B 29.221 25 
SERPINB4 29.221 45 JUP 29.221 82 
PRDX6 29.221 25 PPIF 29.221 22 
SERPINB6 29.221 43 TBCB 29.221 27 
SARS2 29.221 58 ST13 29.221 41 
EPS15 29.221 99 SYNCRIP 29.221 70 
HNRNPH2 29.221 49 CBX3 29.221 21 
DPYSL2 29.221 62 RPL19 29.221 23 
PRDX3 29.221 28 RANBP1 29.221 23 
DDX42 29.221 103 RPL28 29.221 16 
TBCE 29.221 59 PFN1 29.221 15 
CSRP2 29.221 21 RBM10 29.221 104 
CKAP4 29.221 66 LMNB2 29.221 68 
RBM39 29.221 59 HIST1H1E 29.221 22 
EIF6 29.221 27 ACAA2 29.221 42 
PMPCB 29.221 54 HNRNPR 29.221 71 
RPL13A 29.221 24 PDE12 29.221 67 
CSTF1 29.221 48 SF3B4 29.221 44 
PPA1 29.221 33 UBE2N 29.221 17 
MICAL1   29.221 118 LIG3 29.221 113 
TFAM 29.221 29 ERAL1 29.221 48 
SEC22B 29.221 25 CARS 29.221 85 
JUP 29.221 82 UCHL3 29.221 26 
PPIF 29.221 22 SCYL2 29.221 104 
TBCB 29.221 27 CBX1 29.221 21 
ST13 29.221 41 ERO1L 29.221 54 
SYNCRIP 29.221 70 
CBX3 29.221 21 
RPL19 29.221 23 
RANBP1 29.221 23 
RPL28 29.221 16 
PFN1 29.221 15 
RBM10 29.221 104 
LMNB2 29.221 68 
RPL17 29.221 21 
SERPINB4 29.221 45 
PRDX6 29.221 25 
SERPINB6 29.221 43 
SARS2 29.221 58 
EPS15 29.221 99 
HNRNPH2 29.221 49 
DPYSL2 29.221 62 
PRDX3 29.221 28 
DDX42 29.221 103 
TBCE 29.221 59 
CSRP2 29.221 21 
Table&1.&Cont’d&&
